Palisade Bio, Inc. (PALI) — DEF 14A Filings
All DEF 14A filings from Palisade Bio, Inc.. Browse 5 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (5)
-
Palisade Bio Seeks Shareholder Nod for 8.6M Warrant Issuance, Capital Boost
— Oct 28, 2025 Risk: medium
Palisade Bio, Inc. (PALI) is seeking stockholder approval for two key proposals at a Special Meeting on December 3, 2025. Proposal 1 requests approval, under Na -
Palisade Bio Seeks Reverse Stock Split Approval at Annual Meeting
— Sep 15, 2025 Risk: high
Palisade Bio, Inc. (PALI) is holding its 2025 Annual Meeting of Stockholders on October 17, 2025, virtually, to address three key proposals. Stockholders will v -
Palisade Bio Files Definitive Proxy Statement
— Aug 18, 2025 Risk: low
Palisade Bio, Inc. filed its definitive proxy statement on August 18, 2025, for its annual meeting. The company, formerly known as Seneca Biopharma, Inc. and Ne -
Palisade Bio Files Definitive Proxy Statement
— May 22, 2024 Risk: low
Palisade Bio, Inc. filed its definitive proxy statement on May 22, 2024, for its annual meeting of stockholders. The filing details the company's governance, ex -
Palisade Bio, Inc. Announces Special Meeting of Stockholders to Vote on Reverse Stock Split
— Feb 6, 2024 Risk: medium
PALISADE BIO, INC. (PALI) filed a Proxy Statement (DEF 14A) with the SEC on February 6, 2024. Palisade Bio, Inc. will hold a Special Meeting of Stockholders on
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX